HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY

被引：0
|
作者：
Collin, S. [1 ]
Tse, J. [2 ]
Shaikh, N. F. [3 ]
Near, A. [2 ]
Hamilton, E. [4 ]
Brufsky, A. [5 ]
Gradishar, W. [6 ]
Mehta, S. [7 ]
Long, G. H. [1 ]
Toms, N. [1 ]
机构：
[1] AstraZeneca Pharmaceut Ltd, Cambridge, England
[2] IQVIA, Durham, NC USA
[3] IQVIA, Morgantown, WV USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[7] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE417
引用
下载
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [41] ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
    Venetis, Konstantinos
    Pepe, Francesco
    Pescia, Carlo
    Cursano, Giulia
    Criscitiello, Carmen
    Frascarelli, Chiara
    Mane, Eltjona
    Russo, Gianluca
    Salimbeni, Beatrice Taurelli
    Troncone, Giancarlo
    Rocco, Elena Guerini
    Curigliano, Giuseppe
    Fusco, Nicola
    Malapelle, Umberto
    CANCER TREATMENT REVIEWS, 2023, 121
  • [42] Physician experiences and preferences in the treatment of HR+/HER2-metastatic breast cancer in the United States: aphysician survey
    Lin, Peggy L.
    Hao, Yanni
    Xie, Jipan
    Li, Nanxin
    Zhong, Yichen
    Zhou, Zhou
    Signorovitch, James E.
    Wu, Eric Q.
    CANCER MEDICINE, 2016, 5 (02): : 209 - 220
  • [43] TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer
    Rugo, Hope S.
    Bardia, Aditya
    Tolaney, Sara M.
    Arteaga, Carlos
    Cortes, Javier
    Sohn, Joohyuk
    Marme, Frederik
    Hong, Quan
    Delaney, Rosemary J.
    Hafeez, Amir
    Andre, Fabrice
    Schmid, Peter
    FUTURE ONCOLOGY, 2020, 16 (12) : 705 - 715
  • [44] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [45] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [46] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [47] Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+/HER2-metastatic breast cancer treated with abemaciclib
    Saverno, Kimberly R.
    Beyrer, Julie
    Smyth, Emily Nash
    Abedtash, Hamad
    DeLuca, Angelo
    Zhu, Yajun Emily
    Rybowski, Sarah
    CANCER RESEARCH, 2021, 81 (04)
  • [48] Real-world predictors of first-line treatment and descriptive outcomes in HR+/HER2-metastatic breast cancer patients in the US
    Downer, M. K.
    Jhaveri, Komal
    Bardia, Aditya
    Loi, Sherene
    Kent, Matthew
    Luhn, Patricia
    Humke, Eric W.
    CANCER RESEARCH, 2020, 80 (04)
  • [49] Real-world clinical outcomes in US patients with brain metastases secondary to HR+/HER2-metastatic breast cancer treated with abemaciclib
    Gathirua-Mwangi, Wambui
    Martin, Holly
    He, Dan
    Zheng, Shen
    Sheffield, Kristin
    John, Jincy
    Rybowski, Sarah
    Brastianos, Priscilla
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2-Metastatic Breast Cancer Treated with Abemaciclib
    Smyth, Emily Nash
    Beyrer, Julie
    Saverno, Kimberly R.
    Hadden, Elizabeth
    Abedtash, Hamed
    DeLuca, Angelo
    Lawrence, Garreth W.
    Rybowski, Sarah
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (04) : 681 - 693
12345